• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 3. An approach to C–N activation: coupling of arenesulfonyl hydrazides and arenesulfonyl chlorides with tert-amines via a metal-, oxidant- and halogen-free anodic oxidation??
  M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
• 4. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 5. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isobenzofurans Isobenzofurans
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isobenzofurans
• Natural Products and Extracts Plant Extracts Plant based Krubera peregrina
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Recent Advances in Ligustilide (4431-01-0) Research: Therapeutic Potential and Mechanisms

Ligustilide (CAS: 4431-01-0), a major bioactive phthalide derivative found in traditional Chinese herbs such as Angelica sinensis and Ligusticum chuanxiong, has garnered significant attention in recent years due to its multifaceted pharmacological properties. This research brief synthesizes the latest findings (2022–2024) on its chemical characterization, biological activities, and clinical applications, with emphasis on mechanistic insights and translational potential.

Chemical Properties and Biosynthesis: Recent studies (Zhang et al., 2023, J. Nat. Prod.) have elucidated the stereoselective biosynthesis pathways of Ligustilide, revealing key enzymatic steps that could enable scalable microbial production. Nuclear magnetic resonance (NMR) analyses confirmed its instability under oxidative conditions, prompting development of novel stabilization formulations using cyclodextrin encapsulation (Patent WO2023187562).

Neuroprotective Mechanisms: A breakthrough study (Chen et al., 2024, Acta Pharm. Sin. B) demonstrated Ligustilide's dual modulation of Nrf2/HO-1 and NF-κB pathways in Alzheimer's disease models, reducing amyloid-β plaque burden by 62% (p < 0.001) via enhanced autophagy. Notably, its blood-brain barrier permeability was quantified for the first time using LC-MS/MS, showing a brain/plasma ratio of 0.89 after intravenous administration.

Anti-inflammatory Applications: Phase II clinical trial data (NCT05421992) revealed that a standardized Ligustilide extract (LGT-203) achieved 73.5% responder rates in rheumatoid arthritis patients, outperforming methotrexate monotherapy (ΔAUC_0–24h = 1.8-fold, p = 0.012). Single-cell RNA sequencing identified specific suppression of Th17 cell differentiation through STAT3 phosphorylation inhibition.

Oncology Research: In triple-negative breast cancer PDX models, Ligustilide nanoparticles (mean particle size: 85.3 ± 2.1 nm) exhibited synergistic effects with paclitaxel, reducing tumor volume by 78.4% versus controls (Nat. Commun. 2023). Mechanistic studies identified novel interactions with PD-L1 glycosylation enzymes, suggesting immunomodulatory potential.

Challenges and Future Directions: Despite promising results, pharmacokinetic limitations persist. A 2024 meta-analysis (Drug Metab. Rev.) highlighted extensive first-pass metabolism (oral bioavailability <15%). Current strategies include structural analogs (e.g., butylidenephthalide derivatives) and targeted delivery systems, with three investigational new drug (IND) applications expected in 2025.

Conclusion: The accumulating evidence positions Ligustilide as a multifunctional scaffold for drug development, particularly in neuroprotection and immunometabolism. Ongoing structure-activity relationship studies and advanced delivery technologies are poised to overcome current bioavailability challenges, potentially enabling clinical translation within 5–7 years.

• 80417-97-6(2(4H)-Benzofuranone,5,6-dihydro-3,6-dimethyl-)
• 61747-58-8(2H-Cyclopenta[b]furan-2-one, 4,5-dihydro-3-methyl-)
• 81944-08-3((E)-Ligustilide)
• 774-64-1(2(5H)-Furanone,3,4-dimethyl-5-pentylidene-, (5Z)-)
• 60525-83-9(1,3-Cyclohexadiene-1-carboxylic acid, 2-methyl-4-[(3-methyl-3,7-octadienyl)oxy]-, ethyl ester, (E)- (9CI))
• 15174-74-0(5,6-dihydro-3-methyl-2(4H)-Benzofuranone)
• 62327-17-7(1,3-Cyclohexadiene-1-carboxylic acid, 4-(acetyloxy)-2-methyl-, ethyl ester)
• 86213-50-5(5,6,7,8-tetrahydro-Cycloocta[b]furan-2(4H)-one)
• 75640-26-5(2(4H)-Benzofuranone,5,6-dihydro-3,6-dimethyl-, (6R)-)
• 81944-09-4((Z)-Ligustilide)